Novartis, Thai Government Agree To Free Gleevec, No Push For Compulsory License
This article was originally published in PharmAsia News
Novartis and its regional headquarters in Thailand agreed to provide its Gleevec (imatinib mesylate) free to poorer cancer patients in the country in exchange for the government dropping its compulsory licensing threat. The outgoing public health minister who brokered the deal said he would like other drug makers to take similar steps or face compulsory licensing. The deal means Novartis is to offer free access to leukemia and gastrointestinal cancer patients under the universal health care plan and continue marketing the drug to Thais who can afford the market price. In Thailand, the market price is 20 times higher than a generic produced in India. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.